Teclistamab in relapsed or refractory AL amyloidosis, a multinational retrospective case series-Reference-Cited by-同舟云学术

Teclistamab in relapsed or refractory AL amyloidosis, a multinational retrospective case series

Published:2023-12-14 Issue: Volume: Page:
ISSN:0006-4971
Container-title:Blood Journal
language:en
Short-container-title:

Author:

Forgeard Nathalie¹,ELESSA Dikelele¹^ORCID,Carpinteiro Alexander²^ORCID,Belhadj Karim³^ORCID,Minnema Monique C.⁴^ORCID,Roussel Murielle⁵^ORCID,Huart Antoine⁶,Javaugue Vincent⁷,Pascal Laurent⁸^ORCID,Royer Bruno⁹,Talbot Alexis¹,Gounot Romain¹⁰,Hegenbart Ute¹¹^ORCID,Schonland Stefan¹²^ORCID,Karlin Lionel¹³,Harel Stephanie¹⁴,Kastritis Efstathios¹⁵^ORCID,Bridoux Frank⁷,Jaccard Arnaud¹⁶^ORCID,Arnulf Bertrand¹

Affiliation:

1. Université Paris Cité, France

2. University Hospital Essen, Essen, Germany

3. Hopital Henri Mondor, Creteil, France

4. UMC Utrecht, Utrecht, Netherlands

5. University Hospital Limoges

6. University Hospital of Toulouse, Toulouse, France

7. CHU Poitiers, POITIERS, France

8. GHICL, Lille, France

9. Hopital Saint Louis, APHP, paris, France

10. Hôpital Henri Mondor, Créteil, France

11. University Hospital, Heidelberg, Germany

12. University Hospital Heidelberg, Heidelberg, Germany

13. Hôpital Lyon Sud, Pierre-benite, France

14. APHP Hôpital Saint Louis, Paris, France

15. Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

16. CHU Limoges, Limoges, France

Abstract

Teclistamab shows promising results in R/R AL amyloidosis, with VGPR or better in 88% of patients and involved FLC < 10 mg/L in 76%. We observed a 35% rate of severe infections and no cardiac or kidney related events.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

https://ashpublications.org/blood/article-pdf/doi/10.1182/blood.2023022937/2176949/blood.2023022937.pdf

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and efficacy of B cell maturation antigen‐directed CAR T‐cell therapy in patients with relapsed/refractory multiple myeloma and concurrent light chain amyloidosis;European Journal of Haematology;2024-08-27

2. Treatment of AL amyloidosis in the era of novel immune and cellular therapies;Frontiers in Oncology;2024-06-28

3. Systemic Light Chain Amyloidosis;New England Journal of Medicine;2024-06-27

4. Options for Rescue Treatment of Patients with AL Amyloidosis Exposed to Upfront Daratumumab;Current Oncology Reports;2024-06-19

5. High-dose melphalan-autologous hematopoietic cell transplantation in systemic AL amyloidosis following daratumumab-based frontline therapy;Bone Marrow Transplantation;2024-05-09